Skip to content

Even in the Age of the Hundred-Year Life, We Still Want to Stay Young

Living longer raises another question: how much of that time can we spend in good health?

From Bryan Johnson’s pursuit of immortality to research on SRSF1 and aging: can cells become younger while keeping their identity?

In Korea, hwangap—the traditional celebration of one’s 60th birthday—has long marked an important milestone. It signifies the completion of a full cycle in the traditional calendar. As longer lives have become more common, celebrations of turning 70 or 80 have taken on greater prominence. Yet even as we live longer, our desire to stay young remains.

Even as the idea of a hundred-year life becomes familiar, we continue to dream of slowing aging. We buy wrinkle creams, adjust our diets, and exercise to stay fit. Behind those choices is a desire to look younger, but also to live longer in a body that allows us to keep doing the things we enjoy.

As life grows longer, the condition in which we live those extra years matters more.

The Desire to Live Longer—and Bryan Johnson

Entrepreneur Bryan Johnson has turned that desire into a public personal experiment. Through Project Blueprint, which he introduced in 2021, he has tracked his sleep, diet, exercise, and a wide range of health measurements, adjusting his routine along the way.

One experiment that brought him widespread attention involved receiving plasma donated by his son. He later described other experimental interventions, including gene delivery and cell injections. According to his official protocol, in March 2024 he received 300 million bone marrow-derived mesenchymal stem cells (MSCs) in his knees, shoulders, and hips. His stated aim was to reduce age-related joint damage and preserve physical performance. An account published that October described the procedure and plans for evaluating its effects.

Yet in 2026, Johnson also disclosed a new health problem. According to his account, a stomach biopsy in May of that year led to a diagnosis of autoimmune gastritis. This was a separate diagnosis from the autoimmune hypothyroidism identified when he was twenty-one. The stomach condition had only recently been discovered; when it actually began remains unknown. (Johnson’s account of the diagnosis)

His story illustrates the complexity of looking after our health. Looking young, maintaining favorable test results, detecting disease, and preserving physical function are connected goals, but each requires different questions.

Researchers are exploring some of those questions at the level of individual cells. One example is a study published in Nature Aging in October 2026, involving researchers at Harvard, Spain’s CIC bioGUNE, and other institutions. While searching for genes that could shift the gene-expression patterns of older cells toward a younger state, the team identified an RNA-processing factor called SRSF1.

Could changing how cells use their genetic information help them recover some youthful functions while preserving their original role?

The Same DNA, Different Cellular Roles

Skin cells and nerve cells from the same person have largely the same DNA sequence. Their appearance and function differ because they express different genes at different levels and process that information differently. Transcription factors, chromatin structure, and epigenetic marks help establish and maintain these differences. (NIH’s explanation of the epigenome)

This regulatory system underlies cell identity. Fibroblasts in the skin, for example, produce collagen and other components of the extracellular matrix, supporting surrounding tissue and contributing to repair. To perform those tasks, a fibroblast needs to maintain the gene-expression program that supports its function.

Cellular reprogramming changes these regulatory systems to shift a cell’s state. In disease research, it is used to model disease using patient-derived cells or to generate cells that could replace damaged ones. In aging research, a central interest is whether declining function can be restored while preserving the cell’s role.

One established approach uses the Yamanaka factors: OCT4, SOX2, KLF4, and c-MYC, collectively known as OSKM. These four transcription factors reshape gene expression and epigenetic states, allowing differentiated cells to be reprogrammed into induced pluripotent stem cells (iPSCs), which can develop into many different cell types. (Original 2006 study; 2007 study in human cells)

Aging researchers are interested in controlling how far this transition proceeds. The aim of partial reprogramming is to improve some age-related changes while allowing cells to retain their identity.

A 2020 study published in Nature demonstrated this possibility in neurons. The researchers expressed OCT4, SOX2, and KLF4—OSK—in mouse retinal ganglion cells, omitting c-MYC, which is associated with tumor formation. They observed enhanced nerve-fiber regeneration after injury and improved visual function in aged mice and a mouse model of glaucoma.

Gene-expression and DNA methylation patterns also shifted toward a younger state. DNA methylation is a chemical mark involved in regulating gene activity. The observation that molecular changes and functional improvements occurred while neuronal identity was maintained suggested that recovery could be induced without taking cells all the way back to a pluripotent state.

Reading Cellular Changes With an AI Model

The SRSF1 team wanted to explore whether other genes could offer similar possibilities. Their starting point was a measurement tool that could compare the effects of different interventions on a common scale.

Using RNA-sequencing data from human skin fibroblasts obtained from donors of different ages, the researchers developed a machine-learning model to predict transcriptomic age. RNA sequencing measures which genes are expressed and at what levels. The model learned the relationship between those expression patterns and the donors’ actual ages.

Here, chronological age means the time elapsed since birth, while transcriptomic age is an age estimated from gene-expression patterns. A lower score after treatment means that the expression profile more closely resembles that of younger reference cells.

A distinctive feature of the approach was its effort to interpret gene expression through biological processes. The model combined changes across processes such as protein synthesis and quality control, cellular structure, and signaling to compare states before and after an intervention. (The research team’s explanation of the model and screen)

The researchers then conducted a gain-of-function screen, increasing the expression of individual candidate genes in older fibroblasts. In experiments that included 89 candidates, comparison conditions, and a blue fluorescent protein (BFP) control, SRSF1 emerged as a promising candidate.

The model translated complex expression changes into comparable scores, while the experiments showed which genes could produce those changes. The next step was to examine how SRSF1 affected cell identity and actual cellular function.

SRSF1: How RNA Is Processed Matters, Too

SRSF1 stands for serine/arginine-rich splicing factor 1. Its role becomes easier to understand by following the steps between a gene and the protein it produces.

When a gene is transcribed, the initial RNA can contain introns, which are removed, and exons, which are joined together. Cells carry out this editing step through RNA splicing.

Different choices about which exons to include and how to join them can produce several forms of RNA from a single gene. This is called alternative splicing. The resulting transcript variants, or isoforms, can give rise to proteins with different functions or affect how the RNA is maintained and used.

SRSF1 helps regulate this processing. Understanding its role therefore requires looking at both the total amount of RNA and the forms being produced. A gene’s overall expression level can remain similar even while its mix of isoforms changes.

This brings the research question into sharper focus: which changes in RNA processing contribute to the recovery of cellular function? Explaining effects across several functions requires connecting the RNAs altered by SRSF1 with their consequences. The researchers also describe the relationship between specific splicing changes and functional improvement as an area that needs further investigation. (Interview with the research team)

What Changed in the Cells’ Appearance and Function?

Fibroblasts expressing SRSF1 showed gene-expression patterns closer to a younger state, alongside reported reductions in age-related features, inflammatory signaling, and stress associated with maintaining protein homeostasis. They also retained characteristic fibroblast gene expression and their elongated, spindle-shaped appearance.

This is notable alongside the morphological changes observed during OSKM induction: the effects of SRSF1 occurred while the cells preserved their existing characteristics. Cell morphology, considered together with the expression of genes associated with a particular cell type, provides evidence about identity.

Senescence-associated β-galactosidase (SA-βGal) activity also decreased following transient mRNA delivery. In a separate analysis, however, the proportion of p16-positive cells did not change significantly. The age-related markers measured did not all respond in the same way. (Nature Aging, Extended Data Figs. 5–6)

The team also examined function. In a scratch assay, which creates a gap in a cultured cell layer and tracks its closure, SRSF1-treated cells showed a tendency toward faster closure. Measurements of reactive oxygen species (ROS) under oxidative stress also moved downward, although the change was not statistically significant. These observations offer leads for further validation, while calling for a distinction between clearly supported effects and accompanying trends. (Nature Aging, Extended Data Figs. 7–8)

Findings in Mice—and Why Expression Control Matters

The researchers also tested SRSF1 in aged mice. In skin experiments using an AAV8 vector and an inducible expression system, the age-related decline in wound repair was partially improved. In a separate survival experiment, the team reported 44% slower frailty progression and an approximately 14% increase in median lifespan relative to controls. The lifespan analysis included 9–10 mice per group. (Nature Aging, Extended Data Fig. 9)

Lifespan and frailty describe different aspects of the outcome. Lifespan measures how long an animal survives, while a frailty index assesses the accumulation of health deficits with age. Examining both is meaningful, although the effects observed in this small experiment need to be reproduced in independent groups of animals.

Another notable finding was that wound-healing outcomes differed according to how SRSF1 was expressed. Improvement was observed with inducible expression, but the same benefit was not seen with constitutive expression driven by a CAG promoter.

This suggests that how a gene is controlled may matter alongside which gene is selected. Comparing the effects of expression level, timing, and duration could help clarify the conditions needed for functional recovery.

Turning Functional Recovery Into a Lasting Intervention

The next questions are clear. In which tissues should SRSF1 be increased, and by how much? Could a brief intervention produce lasting changes? Could beneficial responses also be achieved in human tissues?

There is a specific biological reason to study expression control carefully. Earlier cancer research, conducted when SRSF1 was known as SF2/ASF, showed that its overexpression could induce transformation in immortalized rodent fibroblasts, which formed tumors when transplanted into mice. Aging research therefore needs to examine both the expression range required for functional recovery and the long-term response of tissues.

This study identifies a possible way to influence age-related cellular states through a regulator of RNA processing. Establishing which changes drive functional recovery could also help researchers find additional candidates and design more precise interventions.

My Thoughts | Perhaps Not Forever, but a Little Longer

When I hear about people pursuing immortality, the idea initially feels unfamiliar. But I cannot say I fail to understand the desire. I, too, want to keep doing the things I enjoy, visit places I have never been, and spend more time with the people I love.

If slowing aging someday becomes an ordinary choice, how long will we say we want to live? An age that seems unimaginable now might feel natural by then. Or perhaps having more time would make us think more carefully about how we want to spend it.

Research into restoring cellular function, such as this SRSF1 study, makes me wonder whether some changes we associate with growing older might eventually be approached differently. It will take time for those possibilities to reach everyday life, but the process of asking what could change is itself fascinating.

I still do not know whether I would want to live forever. I do hope that, as I grow older, there will still be things I want to do—and that I will have the physical and mental capacity to try them. If aging research can give us a little more of that time, that seems reason enough to look forward to the next discovery.

Leave a Reply

Your email address will not be published. Required fields are marked *